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Methods: Breast tissues were collected from 26 BC patients. ER, PR andHER-2 expres-
sion was quantified using immunohistochemistry. MDA-MB-231 TNBC cells were
treated with serial dilutions of hesperitin. miR-486-5p loss and gain of function experi-
ments was performed using lipofection technique. Functional analysis experiments
were carried out such asMTT, colony forming and wound closure assays 48 hrs post-
treatment. 5-Fluro uracil was used as a positive control. Total RNA extraction was per-
formed followed by reverse transcription into cDNA which was quantified using qRT-
PCR. Unpaired student’s t-test was performed using GraphPad 5.0.
Results:miR-486-5p was down-regulated in 100% of BC patients. TNBC patients
showed a selective diminished miR-486-5p levels compared to non-TNBC patients.
Hesperetin markedly decreasedMDA-MB-231 cellular viability and clonogenicity
compared to vehicle control. miR-486-5p mimics repressed cellular viability, clonoge-
nicity andmetastatic potential of TNBC cells thus supporting its reported tumor sup-
pressor activity. While anti-miR-486-5p resulted in an increase in TNBC hallmarks.
Interestingly, a potential crosstalk between hesperitin andmiR-486-5p was witnessed
inMDA-MB-231 where hesperitinmarkedly increasedmiR-486-5p expression.
Conclusions:Hesperitin is a novel anti-neoplastic agent which mediates its anti-
proliferative activity through inducing miR-486-5p levels thus efficiently harnessing
TNBC progression and hijacking its metastatic potential.
Legal entity responsible for the study:German University in Cairo, GUC.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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Background:Nivolumab and pembrolizumab that target the PD-1 immune check
point have recently been approved in recurrent and/or metastatic head and neck squa-
mous cell carcinoma (R/MHNSCC) patients who have failed platinum therapy. We
aimed to evaluate the prognostic value of selected immune genes’ expression in a retro-
spective analysis of 96 untreated HNSCC patients.
Methods:We retrieved 96 HNSCC patients who underwent primary surgery at Institut
Curie between 1990 and 2006. Real-time quantitative RT-PCR was used to analyze a
panel of 46 genes classified in immunity genes and tissue specific genes. Univariate and
multivariate analyses were performed to assess the prognostic value of overexpressed
genes. This study was approved by the internal review board of Institut Curie.
Results:Median age was 56 years [range: 35–78]. 80% of patients were men with a his-
tory of alcohol (70%) and/or tobacco consumption (73%). Twelve patients (12%) were
HPV-positive. Primary tumor location was oral cavity (45%), oropharynx (21%), lar-
ynx (18%), and hypopharynx (17%). Patients had stage I, II, III, and IVa in 10%, 16%,
13%, and 61%, respectively. Median disease-free interval was 23months [range: 0.7-
185]. Most significantly overexpressed genes were OX40L (74%), TNFRSF9 (77%), and
TNFRSF18 (74%) immunity genes, and CD80 (80%) and FOXP3 (62%) tissue specific
genes. Median disease-free interval was 11months in high OX40LmRNA level HNSCC
patients versus 23months in low OX40LmRNA level HNSCC patients (p¼ 0.0009).
Conclusions:OX40L overexpression was associated with a poor outcome in HNSCC
patients treated with primary surgery.
Legal entity responsible for the study: Institut Curie.
Funding: Fondation ARC pour la recherche sur le cancer ICGEx.
Disclosure: All authors have declared no conflicts of interest.
91P A major response to carboplatin in a metastatic triple-negative breast
cancer patient with somatic mutation of BRCA1 and RAD51B: When
chemotherapy meets precision medicine
L. Seguin1, M. Chaffanet2, R. Sabatier1, A. Jose2, S. Garnier2, N. Carbuccia2, A. Guille2,
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Background: Recent clinical data indicate a higher pathological complete response rate
when platinum is added to neoadjuvant chemotherapy in triple-negative breast cancer
(TNBC), and favorable outcomes have also been observed in metastatic TNBC patients
treated with platinum-based regimen. BC associated with germline BRCAmutations
display DNA double-strand break repair defects, which are thought to render them par-
ticularly sensitive to DNA repair targeting drugs such as PARP inhibitors and/or plati-
num analogs. In addition, BRCA1/2 genes promoter methylation, somatic mutation, as
well as other genomic alterations in DNA repair genes may also drive homologous
recombination-deficiency (HRD) and the so-called “BRCAness” phenotype. Yet, their
association with sensitivity to platinum derivatives or PARP inhibitors in BC remains
discussed.
Methods: A 75-year old women with rapidly progressive metastatic TNBC and clinical
resistance to anthracylines, taxanes, capecitabine, pembrolizumab and eribulin was
enrolled in a molecular profiling program (PERMED trial, NCT02342158). To identify
clinically-actionable gene mutations and putative druggable pathways, a pretreatment
biopsy of liver metastatic tissue was obtained and analyzed by whole genome array-
CGH (aCGH) and targeted next-generation sequencing (NGS) of 559 cancer genes,
along with germline sequencing. Gene copy number aberrations (CNAs) and somatic
mutation status that could help therapeutic decision were examined.
Results:No germline BRCAmutation was found. The aCGH analysis showed a
genomic instability associated with a BRCAness profile and anHRD score of 19. The
CNAs analysis showed a focal homozygous loss of RAD51B/RAD51L1 gene, while NGS
identified a somatic mutation of BRCA1. Patient received carboplatin single-agent and
developed a durable and almost complete response.
Conclusions: These data strongly suggest that carboplatin may be highly effective in
advanced TNBCwith no germline BRCAmutation but somatic genomic alterations
disrupting DNA repair pathways, supporting precision medicine trials evaluating plati-
num derivatives in this setting.
Legal entity responsible for the study: Institut Paoli Calmettes.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
92P Next-generation sequencing reveals high intra-individual molecular
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Background: Recurrent or metastatic head and neck squamous cell carcinoma
(HNSCC) is an uncurable disease and is responsible of 4 000 deaths every year in
France. Targeted therapies improve outcomes in several types of cancer and lead to
development of the prescription of drugs according to the molecular features of the
tumor, called “precisionmedicine”. The need to perform recent biopsy to perform
thosemolecular analyses is a critical restriction and limits inclusion of patients into pre-
cision medicine programs.
Methods: To compare molecular profiles of primitive tumor and recurrence, we ana-
lyzedmolecular alterations in primary HNSCC and paired local or distant recurrences
from 31 patients using targeted next-generation sequencing (MiniSeq, Illumina), of 42
“cancer-associated” genes (Solid Tumor Solution, Sophia Genetics).
Results: Primary tumors and recurrences harbored alterations common in HNSCC.
Themost frequent were TP53mutations (76%), CDKN2Amutations (21%), PIK3CA
mutations (16%), METmutations (16%) and EGFR amplifications (8%). Twenty-six
patients (83.9%) showed concordant molecular profiles between primary tumors and
matched local or distant recurrences. Fifteen patients harbored alterations with poten-
tial therapeutic implications (mostly tyrosine kinase receptor genes or oncogenes acti-
vation) according to local Molecular Tumor Board criteria. Twenty-seven out of the 31
patients (87.1%) had concordant molecular profile between primary and recurrence
when considering only these “druggable” alterations.
Conclusions:HNSCC primary tumors andmetastases exhibit an intra-individual high
genomic concordance. As these patients had limited therapeutic options, inclusion in
precision medicine programs represents an important opportunity and should be
allowed regardless of the origin of the sample, the primary tumor or its recurrence.
Legal entity responsible for the study:Centre Antoine Lacassagne.
Funding: Centre Antoine Lacassagne.
Disclosure: All authors have declared no conflicts of interest.
93P Decreasing telomerase activity of adenocarcinoma cancer cell line (AGS)
is associated with different concentrations of sodium selenite and
cadmium chloride and selenium l methionine
S.S. Hosseini-Asl1, A. Fazabakhsh1, M. Sagha2
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Background: Selenium (Se) has been recognized as an essential element for animals
and humans. In the late 1960s, it was first suggested that seleniummight have anti-
cancer properties. Selenium controls apoptosis in cell cycle. Cadmium (Cd) is a widely
used heavy metal that affects human health through occupational and environmental
exposure and has been reported as a cause of cancers such as lung, prostate and kidney.
The previous studies on Ovarian and breast cancer have shown that cadmium increases
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telomerase activity and expression level of hTERT. In the present study, we find out the
effect of sodium selenite and selenium lmethionine and cadmium chloride on telomer-
ase activity in adenocarcinoma cancer cell line (AGS).
Methods: The adenoma carcinoma gastric cancer cells (AGS) were cultured in
RPMI1640 supplemented with 10% fetal bovine serum (FBS) and 1% pen/strep.
Concentrations of cadmium chloride, selenium lmethionine and sodium selenite were
added the adenocarcinoma gastric cancer cells (AGS). Finally, the telomerase activity
was measured by telomeric repeat amplification protocol (TRAP) and qRT-TRAP
assays.
Results:Average telomerase activity (as threshold cycle (CT)) has been detected for
three concentrations (5lMand 10lMand 20 lM) of the noted compounds. The results
were 24.8260.51, 25.3161 and 25.6361.32 for Sodium selenite, 24.5660.25,
25.2960.98 and 25.6061.21 for Cadmium chloride and 24.4960.18, 25.3060.99 and
25.7361.32 for Seleniul l methionine, respectively. Representing the signification
decreasing telomerase activity at treated samples compared with the controls
(p 0.05).
Conclusions:Decreasing in the telomerase activity which was caused by treating with
Cadmium chloride, Selenium lmethionine and Sodium selenite is in conflict with
some previous findings indicating the increasing in the telomerase activity by treating
Cadmium.
Legal entity responsible for the study: Ardabil University of Medical Sciences.
Funding: Ardabil University of Medical Sciences.
Disclosure: All authors have declared no conflicts of interest.
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Background:Gliomas are the most frequent CNS primary tumours, which account for
up to 80% of brain malignancies. Important diagnostic and prognostic factor, and
recently significant WHO glioma classificationmarker as well, is mutational status of
IDH1/2 genes. Moreover, search for another markers with predictive character is
needed. Methylation status of MGMT gene promoter is one of relevant predictive
markers, connected with therapeutic response to chemotherapy.
Methods: 260 glioma samples were biopted or surgically resected at Neurosurgery
Clinics withinMoravian – Silesian Region, Czech Republic. DNAwas extracted from
native tissue samples. IDH1/2 gene mutation detection was performed with extension
primer method – SnaPshotVR assay. MGMT gene promoter methylation status was
tested by nested methylation-specific PCR and real-time PCR, preceded by bisulfite
conversion of DNA samples.
Results:Analysis of 260 glioma samples was performed. Out of this, 218 samples were
histopatologically diagnosed as high-grade (HG) gliomas and 42 samples were classi-
fied as low-grade (LG) gliomas. Median age of all patients was 60 years (range 24 – 82
years) at the time of diagnosis. 55 % of patients were men. IDH1 gene mutations were
detected in 29, 2 % (76/260) of patients, MGMT gene promoter methylation was
detected in 60, 8 % (158/260) of patients. IDH2 gene mutations were not detected.
Median overall survival (mOS) was 9 months longer in patients with HG glioma and
IDH1 gene mutation than in patients without mutation. If complete set of HG and LG
gliomas was included, 11 months difference of mOS has been reached. Furthermore,
statistically significant difference of mOS among the group of patients with IDH1 gene
mutations and without mutations has been reached (p value< 0.001 and p< 0.001,
respectively).
Conclusions:Observed relationship of IDH1 gene occurrence tomedian OS in patients
with primary glioma was statistically significant. MGMT gene promoter methylation
did not have any statistically significant influence to OS in observed HG glioma
patients.
Legal entity responsible for the study: CGB Laborator a.s.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
95P First report of ZNF518B gene expression as a prognostic factor in
colorectal cancer development: Role in tissue invasiveness
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Background:Colorectal cancer (CRC) represents a relevant public health problem.
Despite new therapeutic advances, prognosis of patients diagnosed with advanced disease
is still poor. The identification of newmarkers involved in themechanisms of invasiveness
represents a priority in order to better understand cancer development and generate new
therapeutic targets.We describe here the possible role of ZNF518B, a gene not yet well
characterised, on tissue invasion.Human ZNF518B gene, which encodes a putative, zinc
finger-containing transcription factor, yields twomajor alternative splicing isoforms.
Methods: Expression of ZNF518B was determined by RT-qPCR in several CRC cell
lines and in a commercial cDNA array from CRC patients. To explore the mechanisms
that relate the expression of the gene with tumourogenesis, the effects of silencing
ZNF518B on the phenotype of human CRC cell lines has been studied. Among these
experiments, we have performed apoptosis assays by flow cytometry, proliferation by
MTT assays, invasion andmigration assays using transwells and adhesion to type I col-
lagen plates assays.
Results: The analysis of a cDNA array from CRC patients showed that the expression of
the whole gene and of its twomajor isoforms is significantly increased in tumour tissues
when compared to normal mucosa. By the analysis in CRC cell lines, we have demon-
strated that the gene is not involved in cell proliferation, but plays a significant role in
cell migration and invasiveness. These data, together with the changes in the epithelial-
to-mesenchymal transition markers, strongly suggest that ZNF518B plays a role in
tumour cell dissemination.
Conclusions: ZNF518Bmight therefore be a candidate for invasiveness prognosis.
Legal entity responsible for the study: INCLIVA-Universidad de Valencia.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
96P ERBB2 and PI3KCA mutations in endocrine resistant breast cancer (BC)
M. Venturelli1, A. Toss1, F. Piacentini1, I. Bernardis2, E. Tenedini2, C. Omarini1,
L. Moscetti1, S. Cascinu1, E. Tagliafico2, L. Cortesi1
1Department of Oncology and Hematology, Azienda Ospedaliero - Universitaria
Policlinico di Modena, Modena, Italy, 2Department of Medical and Surgical Sciences,
University of Modena and Reggio Emilia, Italy, Center for Genome Research, University
of Modena and Reggio Emilia, Italy, Modena, Italy
Background: An increasing number of molecularly targeted drugs are now available
and, for some of these therapies, predictive biomarkers have already been identified. In
particular, mutations in ERBB2might represent an alternative mechanism for HER2
activation. They occur more frequently in HER2-negative (HER2-) tumors and seem
to be good target for HER2 therapy. Furthermore, PI3KCAmutations showed to pre-
dict sensitivity to Fulvestrant, Buparlisib, Taselisib and resistance to Lapatinib. We
evaluated the incidence of ERBB2 and PI3KCAmutations in 14 hormone receptor
(HR)-positive BC and in their matched endocrine-resistant recurrences.
Methods:We evaluated a panel of genes including ERBB2 and PI3KCA, in FFPE tis-
sues. We analysed 14HR-positive BCs and their matched recurrences. All the relapses
have been developed during an endocrine treatment.
Results: 4/14 pts were diagnosedwithHER2þ BC, while 10/14 pts developedHER2- BC.
Overall, we found 8 differentmutations of ERBB2 in 9 samples: A356D,Q1206X,Q396X,
Q393X, P523L, I654V,G1220C, 135þ 3G>T.We found 6 differentmutations of PI3KCA
in 10 samples: N345K, V344M, E542K, E545K, A1035V,H1047R. ERBB2mutations were
found in the 28.6% of primary tumors and in the 35.7% of relapsed sites. PI3KCAmuta-
tions were found in the 35.7% of primary tumors and in the 35.7% of relapsed sites.mOS
in PI3KCAmutated pts was 112,8months, whilemOS in PI3KCAwild-type pts was 99.
mOS inHER2þ and/or ERBB2mutated pts was 115.6months, whilemOS inHER2-
ERBB2wild type pts was 97.5.mDFS in PI3KCAmutated pts was 41.2months, while
mDFS in PI3KCAwild-type pts was 28.mDFS inHER2þ and/or ERBB2mutated pts was
46.4months, whilemDFS inHER2-wild-type pts was 28.5.
Conclusions:We found an overall detection rate of ERBB2mutations higher than that
described in literature, while PI3KCAmutations were in line with the literature. The
identification of ERBB2 or PI3KCAmutation might justify a more targeted neo/adju-
vant approach andmight guide the subsequent treatment choices. According to the lit-
erature, pts with PI3KCAmutation showed better prognosis, while, contrary to the
previous literature, in our study the majority of ERBB2mutations occurred in HER2þ
samples and HER2þ and/or ERBB2mutated samples did not show worse outcomes.
Legal entity responsible for the study:Marta Venturelli.
Funding: Angela Serra Association.
Disclosure: All authors have declared no conflicts of interest.
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